Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and
pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an …

In this 13th annual installment of the annual 'Antibodies to Watch'article series, we discuss
key events in commercial antibody therapeutics development that occurred in 2021 and …

Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against
the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the devastating global COVID-19 pandemic announced by WHO in March 2020. Through …